BioLife Solutions (NASDAQ:BLFS) Given New $30.00 Price Target at HC Wainwright

BioLife Solutions (NASDAQ:BLFS - Free Report) had its target price boosted by HC Wainwright from $27.00 to $30.00 in a report published on Thursday, Marketbeat.com reports. They currently have a buy rating on the medical equipment provider's stock.

Several other equities research analysts also recently issued reports on the stock. KeyCorp raised their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. Northland Securities lifted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. TD Cowen upped their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Benchmark reissued a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.86.

Remove Ads

BioLife Solutions Stock Down 3.8 %

BLFS traded down $0.97 during midday trading on Thursday, hitting $24.86. 648,726 shares of the company's stock traded hands, compared to its average volume of 350,114. BioLife Solutions has a one year low of $14.84 and a one year high of $29.55. The stock's fifty day simple moving average is $26.65 and its 200-day simple moving average is $25.49. The company has a market cap of $1.17 billion, a PE ratio of -23.45 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The firm had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. During the same quarter last year, the firm posted ($0.21) EPS. As a group, equities analysts anticipate that BioLife Solutions will post -0.3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the transaction, the chief financial officer now directly owns 121,779 shares of the company's stock, valued at $3,290,468.58. This represents a 0.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Aby J. Mathew sold 7,604 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares of the company's stock, valued at $7,551,688.95. This trade represents a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,978 shares of company stock worth $322,724. Company insiders own 2.20% of the company's stock.

Institutional Trading of BioLife Solutions

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new stake in shares of BioLife Solutions in the fourth quarter valued at approximately $20,664,000. Massachusetts Financial Services Co. MA acquired a new position in BioLife Solutions in the fourth quarter valued at about $19,805,000. Point72 Asset Management L.P. acquired a new stake in BioLife Solutions during the fourth quarter worth about $11,113,000. Millennium Management LLC increased its holdings in BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock valued at $29,733,000 after buying an additional 377,111 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its position in shares of BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider's stock worth $14,661,000 after acquiring an additional 262,504 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.